Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 18%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is a promising company in the clinical-stage biopharmaceutical industry, with a novel approach to developing treatments for central nervous system disorders. Although their once-daily regimen for ML-007C-MA did not meet statistical significance on the primary endpoint, the drug still showed numerical improvement and separation on several secondary endpoints in their Phase 2 ZEPHYR trial. The company plans to engage with the FDA to discuss the path forward for ML-007C-MA and has sufficient funding to continue their comprehensive development plans. While the next catalyst for the company will be the top-line data from their VISTA trial in 2027, there is also the potential for positive readthroughs from data on similar drugs being developed by other companies.

Bears say

MapLight Therapeutics is facing several fundamental challenges that could hinder its long-term growth and profitability. These include a pipeline that is focused on difficult-to-treat neuropsychiatry and neurodegenerative conditions, high risks of trial failures, potential lack of FDA acceptance and approvals, and dilutive capital raising activities. Additionally, the company may face intense competition, pricing pressure, and insufficient resources for successful commercialization, which could impact its performance and long-term viability.

MPLT has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 18% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Buy based on their latest research and market trends.

According to 11 analysts, MPLT has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.